On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

CRISPR Therapeutics' stock decline is likely ... and Transfusion-Dependent Beta Thalassemia (TDT) early on. Despite this similarity, the two companies are not similarly situated.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR Therapeutics CRSP is expected to report ... blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia (TDT) — in the United States and Europe.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Shares of CRISPR Therapeutics CRSP have lost more than ... and transfusion-dependent beta-thalassemia (TDT) — in the United States and Europe. Both SCD and TDT indications have a significant ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...